Why this East Bay biotech company shed half its value
February 07, 2019 at 17:44 PM EST
Sangamo's zinc finger nucleases are competing with another technology, known as CRISPR, to show which one is most accurate and efficient in snipping genes and replacing the cut-out section with a correct version.